Search
Hutchison China MediTech (00013.HK) Secures Approval for Savolitinib® and Tagrisso® Combination Therapy in China
1 week ago /
Read about 0 minute
Author：小编
The National Medical Products Administration of China has granted approval for the combination therapy of Savolitinib® (HMPL-504) and Tagrisso® (Osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who possess EGFR mutations, have experienced disease progression following EGFR TKI treatment, and exhibit MET amplification. This approval, anchored on the results of the SACHI Phase III clinical trial, will trigger a milestone payment of US$11 million for AstraZeneca.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
